Intravesical BCG: A Double-Edged Sword? The Untold Story of Infection Risks
<i>Background and Objectives:</i> Intravesical Bacillus Calmette-Guérin (BCG) therapy remains a cornerstone in the treatment of non-muscle-invasive bladder carcinoma due to its efficacy in reducing recurrence and progression rates. However, its use is associated with various complication...
Saved in:
| Main Authors: | Orçun Barkay, Ercüment Keskin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/61/3/379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real‐world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non‐muscle invasive bladder cancer—Implications for global shortage
by: Amandeep Arora, et al.
Published: (2025-06-01) -
Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
by: Dong Ha Kim, et al.
Published: (2024-12-01) -
Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol
by: Roberta Monardo, et al.
Published: (2025-01-01) -
Predictive value of tumor invasion patterns on intravesical bacillus Calmette–Guérin response for stage T1 high-grade non-muscle-invasive bladder cancer
by: Ismail Ulus, et al.
Published: (2025-07-01) -
Intravesical Therapy of Superficial Urothelial Bladder Cancer with BCG and Epirubicin 50 Mg - Comparative Analysis
by: Boyan Atanasov, et al.
Published: (2022-06-01)